evolocumab
General
Pronunciation:
e-vo-lo-kyoo-mab

Trade Name(s)
- Repatha
Ther. Class.
lipid-lowering agents
Pharm. Class.
proprotein convertase subtilisin kexin type9 pcsk9 inhibitors
monoclonal antibodies
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Vallerand, April Hazard., et al. "Evolocumab." Davis's Drug Guide, 18th ed., F.A. Davis Company, 2023. Nursing Central, nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/110362/10/evolocumab.
Vallerand AHA, Sanoski CAC, Quiring CC. Evolocumab. Davis's Drug Guide. F.A. Davis Company; 2023. https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/110362/10/evolocumab. Accessed December 3, 2023.
Vallerand, A. H., Sanoski, C. A., & Quiring, C. (2023). Evolocumab. In Davis's Drug Guide (18th ed.). F.A. Davis Company. https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/110362/10/evolocumab
Vallerand AHA, Sanoski CAC, Quiring CC. Evolocumab [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2023. [cited 2023 December 03]. Available from: https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/110362/10/evolocumab.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - evolocumab
ID - 110362
A1 - Sanoski,Cynthia A,
AU - Vallerand,April Hazard,
AU - Quiring,Courtney,
BT - Davis's Drug Guide
UR - https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/110362/10/evolocumab
PB - F.A. Davis Company
ET - 18
DB - Nursing Central
DP - Unbound Medicine
ER -